根据美国证券交易委员会最新备案文件显示，基因治疗公司4D Molecular Therapeutics（股票代码：FDMT）可能通过多次证券发行筹集最高达4亿美元资金。
这家生物技术企业在其提交的S-3混合储架发行注册声明中披露了该融资计划。该注册声明允许公司在未来三年内根据市场条件择机进行证券销售，具体发行时间、规模及条款将视情况而定。
潜在发行的证券类型可能包括普通股、优先股、认股权证及债务证券等多元组合。公司表示，募集资金将用于推进基因治疗产品管线的临床开发、扩大生产能力以及一般企业用途，其中可能涉及收购互补技术或业务。
此次备案为4D Molecular Therapeutics提供了灵活的融资机制，使其能够根据研发进展和市场需求适时获取资金支持。该公司的基因治疗平台专注于针对眼科、心脏病和神经学等疾病领域开发靶向疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.